← Back to headlines
Ultragenyx Downgraded to Neutral by Goldman Sachs on Setrusumab Data
Ultragenyx Pharmaceutical Inc. has been downgraded to a 'neutral' rating by Goldman Sachs, following the release of new data concerning its drug setrusumab.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
